Grantham, Mayo, Van Otterloo & Co (GMO)
BIO icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,784
Closed -$14.1M – 628
2024
Q4 		$14.1M Sell
42,784
-40,015
-48% -$13.6M 0.05% 225
2024
Q3 		$27.7M Sell
82,799
-13,334
-14% -$4.23M 0.09% 158
2024
Q2 		$26.3M Buy
96,133
+2,781
+3% +$809K 0.09% 152
2024
Q1 		$32.3M Sell
93,352
-5,738
-6% -$1.89M 0.12% 126
2023
Q4 		$32M Buy
99,090
+16,647
+20% +$5.22M 0.14% 125
2023
Q3 		$29.6M Buy
82,443
+5,339
+7% +$2.06M 0.14% 134
2023
Q2 		$29.2M Buy
77,104
+11,704
+18% +$4.76M 0.14% 133
2023
Q1 		$31.3M Sell
65,400
-1,800
-3% -$843K 0.16% 132
2022
Q4 		$28.3M Buy
67,200
+10,800
+19% +$4.36M 0.15% 137
2022
Q3 		$23.5M Buy
56,400
+2,700
+5% +$1.35M 0.14% 166
2022
Q2 		$26.6M Buy
53,700
+9,200
+21% +$4.79M 0.14% 148
2022
Q1 		$25.1M Buy
44,500
+15,400
+53% +$9.28M 0.12% 163
2021
Q4 		$22M Buy
29,100
+6,500
+29% +$4.86M 0.11% 161
2021
Q3 		$16.9M Buy
22,600
+3,000
+15% +$2.25M 0.08% 189
2021
Q2 		$12.6M Buy
+19,600
New +$11.9M 0.06% 222
2019
Q2 		– Sell
-2,200
Closed -$672K – 707
2019
Q1 		$672K Sell
2,200
-100
-4% -$27K ﹤0.01% 539
2018
Q4 		$534K Hold
2,300
– – ﹤0.01% 427
2018
Q3 		$720K Sell
2,300
-300
-12% -$93.1K ﹤0.01% 410
2018
Q2 		$750K Hold
2,600
– – 0.01% 408
2018
Q1 		$650K Buy
2,600
+100
+4% +$25.5K ﹤0.01% 437
2017
Q4 		$597K Buy
+2,500
New +$606K ﹤0.01% 444

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s BIO Position: Q1 2025 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 42,784 shares — an estimated $14.1M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in BIO in Q4 2017 and held it in 21 quarters. The position peaked at $32.3M in Q1 2024. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 42,784 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $14.1M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 21 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Bio-Rad Laboratories Class A position peaked at $32.3M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2025, filed 14 May 2025.